Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Details Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

2008-07-15

2008-07-15

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S576000

Reexamination Certificate

active

07399758

ABSTRACT:
The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

REFERENCES:
patent: 2006/0046983 (2006-03-01), Hudyma et al.
patent: WO 2005/080399 (2005-09-01), None
patent: WO 2006/046030 (2006-05-01), None
patent: WO 2006/046039 (2006-05-01), None

Affiliated with

Also associated with

Rating

Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2741856